參考文獻/References:
[1] Slamon D J, Clark G M, Wong S G, et al.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene[J].Science, 1987, 235(4785): 177-182.
[2] Puglisi F, Minisini A M, De Angelis C,et al.Overcoming treatment resistance in HER2-positive breast cancer: potential strategies[J].Drugs,2012,72(9):1175-1193.
[3] Scaltriti M, Chandarlapaty S, Prudkin L, et al.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor[J].Clin Cancer Res, 2010, 16(9): 2688-2695.
[4] Roberts P J, Bisi J E, Strum J C, et al.Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy[J].Journal of the National Cancer Institute, 2012, 104(6):476-487.
[5] Finn R S,Martin M,Rugo H S,et al.Palbociclib and letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
[6] Hortobagyi G N, Stemmer S M, Burris H A, et al.Ribociclib as first line therapy for HR-positive, advanced breast cancer[J].N Engl J Med, 2016, 375(18):1738-1748.
[7] Goetz M P, Toi M, Campone M, et al.MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol, 2017, 35(32):3638-3646.
[8] Diaz-Rodriguez E, Perez-Pena J, Rios-Luci C, et al.TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells[J].Cancer Lett, 2019, 453: 34-44.
[9] Yang L, Li Y, Bhattacharya A, et al.A recombinant human protein targeting HER2 overcomes drug resistance in HER2-positive breast cancer[J].Sci Transl Med, 2019, 11(476):eaav1620.
[10] 謝韶,丁健,陳奕. CDK抑制劑在抗腫瘤領域的研發(fā)進展[J]. 藥學進展, 2015, 39(10): 734-745.
[11] Herrera Gayol A, Jothy S.Adhesion proteins in the biology of breast cancer: contribution of CD44[J].EXP Mol Pathol,1999,66(2):149-156.
[12] Kleiner D E, Stetler Stevenson W G.Matrix metalloproteinases and metastasis[J].Cancer Chemother Pharmacol, 1999,43(suppl):S42-S51.
[13] Hanahan D,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J].Cell,1996,86(3):353-364.
[14] Muntasell A, Cabo M, Servitja S, et al.Interplay between natural killer cells and anti-HER2 antibodies: perspectives for breast cancer immunotherapy[J].Front Immunol, 2017, 8:1544.
[15] Loi S, Giobbie-Hurder A, Gombos A, et al.Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer(PANACEA): a single-arm,multicentre, phase 1b-2 trial[J].Lancet Oncol, 2019, 20(3):371-382.
[16] Bang Y J,Giaccone G,Im S A,et al.First-in-human phase 1 study of margetuximab?(MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors[J].Ann Oncol,2017,28(4):855-861.
[17] Varella L, Abraham J, Kruse M.Revisiting the role of bevacizumab in the treatment of breast cancer[J].Semin Oncol,2017,44(4):273-285.